Dendreon Corp., of Seattle, reported that preliminary data from a long-term analysis of the phase II STAND study suggested tumor-specific T-cell responses appear to be enhanced and sustained when Provenge (sipuleucel-T) is given following androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer at high risk for metastases.